β2微球蛋白是接受R-CHOP治疗的弥漫性大B细胞淋巴瘤患者的一个强有力的预后因素。
Beta-2 microglobulin is a strong prognostic factor in patients with DLBCL receiving R-CHOP therapy.
作者信息
Miyashita Kazuho, Tomita Naoto, Taguri Masataka, Suzuki Taisei, Ishiyama Yasufumi, Ishii Yoshimi, Nakajima Yuki, Numata Ayumi, Hattori Yukako, Yamamoto Wataru, Miyazaki Takuya, Tachibana Takayoshi, Takasaki Hirotaka, Matsumoto Kenji, Hashimoto Chizuko, Takemura Sachiya, Yamazaki Etsuko, Fujimaki Katsumichi, Sakai Rika, Motomura Shigeki, Ishigatsubo Yoshiaki
机构信息
Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan.
Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan.
出版信息
Leuk Res. 2015 Aug 29. doi: 10.1016/j.leukres.2015.08.016.
Useful prognostic markers for patients with diffuse large B cell lymphoma (DLBCL) have been reported. To identify which biomarker best predicts the prognosis of patients with DLBCL, we performed a retrospective study that included 319 DLBCL patients who had received rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) therapy between 2003 and 2012. We assessed the prognostic significance of six biomarkers [lactate dehydrogenase, soluble interleukin-2 receptor, thymidine kinase activity, beta-2 microglobulin (B2M), C-reactive protein, and ferritin] and representative clinical characteristics using progression-free survival (PFS) as the endpoint. The study group included 181 men and 138 women with a median age of 63 years (range, 22-89 years). In a multivariate analysis, the serum B2M level most strongly correlated with PFS (hazard ratio, 2.11; P=0.04). In a univariate analysis, patients with serum B2M levels >1.75μg/mL (n=210) had a worse 3-year PFS rate (71.2%) than those with B2M levels <1.75μg/mL (n=109; 90.0%). Therefore, serum B2M level at the time of diagnosis is a useful prognostic indicator in DLBCL patients receiving R-CHOP.
已有关于弥漫性大B细胞淋巴瘤（DLBCL）患者的有用预后标志物的报道。为了确定哪种生物标志物能最好地预测DLBCL患者的预后，我们进行了一项回顾性研究，该研究纳入了2003年至2012年间接受利妥昔单抗、环磷酰胺、阿霉素、长春新碱和泼尼松（R-CHOP）治疗的319例DLBCL患者。我们以无进展生存期（PFS）为终点，评估了六种生物标志物[乳酸脱氢酶、可溶性白细胞介素-2受体、胸苷激酶活性、β2微球蛋白（B2M）、C反应蛋白和铁蛋白]以及代表性临床特征的预后意义。研究组包括181名男性和138名女性，中位年龄为63岁（范围22-89岁）。在多变量分析中，血清B2M水平与PFS的相关性最强（风险比，2.11；P=0.04）。在单变量分析中，血清B2M水平>1.75μg/mL的患者（n=210）3年PFS率（71.2%）低于B2M水平<1.75μg/mL的患者（n=109；90.0%）。因此，诊断时的血清B2M水平是接受R-CHOP治疗的DLBCL患者的一个有用的预后指标。
Zotero 插件